OMT Therapeutics, Inc. – Trademark Portfolio
Entity Type: 03
OMT Therapeutics, Inc. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 4 filings in this category. The portfolio also extends into Class 31 (Natural Agricultural Products) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include UNIAB, UNIDAB, and UNIRAT. The owner is based in Palo Alto, CA.
2747 Ross Road, Suite A
Palo Alto, CA 94303
Showing of trademarks Trademarks
Trademark Classifications
OMT Therapeutics, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Raw and unprocessed agricultural, aquacultural, horticultural and forestry products
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does OMT Therapeutics, Inc. have?
OMT Therapeutics, Inc. has 5 U.S. trademarks filed with the USPTO. Of these, 3 registered, 2 abandoned.
What trademark classes does OMT Therapeutics, Inc. file in?
OMT Therapeutics, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 31 (Natural Agricultural Products), Class 42 (Computer & Scientific). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are OMT Therapeutics, Inc.'s most well-known trademarks?
OMT Therapeutics, Inc.'s registered trademark portfolio includes well-known marks such as UNIAB, UNIDAB, and UNIRAT. These are among 3 currently registered trademarks in the portfolio.
What is OMT Therapeutics, Inc.'s trademark registration success rate?
OMT Therapeutics, Inc. has a 60% trademark registration rate, with 3 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.